Key GOP Congressman Opposed 340B Amendment to Spending Bill During Committee Hearing

Rep. Michael Burgess (R-Texas) this week cited ongoing 340B contract pharmacy litigation in cautioning against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

An influential Republican congressman on Monday cautioned against amending federal spending legislation to rebuke six drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.

Please Login or Become a Paid Subscriber to View

Read More »

340B Won’t be Overlooked if There’s a Grand Bargain on Drug Pricing, Analyst Predicts

340B “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicts.

The 340B program “will not be overlooked” if the drug industry strikes a grand bargain with Congress and the Biden administration on lowering drug prices, biopharma policy analyst Michael McCaughan predicted this week during a talk on drug pricing reform

Read More »

Kalderos Urges Feds to Protect Hospitals from Losing 340B Eligibility During Pandemic

Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.

Drug industry vendor Kalderos is urging leaders in Washington to temporarily shield hospitals from losing their 340B eligibility during the COVID-19 pandemic.

Please Login or Become a Paid Subscriber to View this Content

Read More »

News Alert: U.S. House Votes to Highlight Need to Halt Pharma’s “Unlawful” 340B Actions

U.S. Rep. Abigail Spanberger (D-Va.) said her successful amendment today to a spending bill sends big pharma the message "Stop hiking drug prices on consumers and discriminating against our 340B providers and pharmacies."
The U.S. House voted this evening “to highlight the need to protect the integrity of the 340B program by halting pharmaceutical manufacturers' unlawful actions that have resulted in overcharges to 340B covered entities.”

Please Login or

Read More »

House GOP Starts Crafting Health Care Bills in Anticipation of Retaking Majority

U.S. Rep. Brett Guthrie (R-Ky.) is a co-leader of the House GOP's Healthy Future Task Force. He is also the ranking GOP member on the House committee overseeing 340B.
The top Republicans on two U.S. House health subcommittees are leading a party effort to “craft legislative proposals that Republicans can advance after retaking the majority” in the November 2022 midterm elections. It is not known whether the group will
Read More »

Key Congressional Committee Urges HRSA to Fine Drug Makers Over 340B Contract Pharmacy Denials

U.S. House appropriators are encouraging HRSA to use fines and "any available measures" to hold drug manufacturers accountable for withholding 340B drug discounts.
The U.S. House Appropriations Committee is pleased with the U.S. Health Resources and Services Administration (HRSA) for challenging six drug makers’ denials of 340B pricing when covered entities use contract pharmacies, the committee said in a report released yesterday. It
Read More »

House Appropriators Want an Update from HRSA on its Plans to Clarify 340B Patient Definition and Provider Eligibility Criteria, Calls for New GAO Report

House appropriators want GAO to update its pivotal 2011 report on 340B, and want HRSA to report on its plans to implement the report's remaining two recommendations, which focus on clarifying eligibility criteria for 340B patients and providers.

In addition to weighing in on the ongoing 340B contract pharmacy standoff (see related story), the U.S. House Appropriations Committee has entered the thicket of the highly controversial topics of 340B patient definition and provider eligibility.

In its report

Read More »

Rosen Introduces Bill to Boost Nonprofit Drug Makers’ Competitiveness

U.S. Sen. Jacky Rosen's (D-Nev.) bill, S. 2257, is aimed at boosting nonprofit drug companies' competitiveness.

U.S. Sen. Jacky Rosen (D-Nev.) has introduced legislation to help nonprofit drug companies compete in the market with their for-profit counterparts.

Rosen’s bill S. 2257, the Expanding Access to Affordable Prescription Drugs and Medical Devices Act, would make it simpler

Read More »

News Alert: Bipartisan Bill Introduced to Protect 340B Providers From Reimbursement Cuts and Address Duplicate Discount Challenge

Reps. David McKinley (R-WV) and Abigail Spanberger (D-VA) introduced legislation today to address so called pickpocketing of 340B provider savings and establish a clearinghouse to address duplicate discounts.
Reps. David McKinley (R-WV) and Abigail Spanberger (D-VA) introduced the PROTECT 340B Act today, which would prohibit pharmacy benefit managers (PBMs) and other third-party payers from paying 340B providers below-market rates or engaging in other perceived discriminatory contracting practices. While
Read More »
Generic selectors
Exact matches only
Search in title
Search in content